Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03612960
Other study ID # 9276
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 20, 2020
Est. completion date January 2024

Study information

Verified date November 2023
Source Milton S. Hershey Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal of this study is to determine if switching to very low nicotine content cigarettes changes the function of brain circuitry involved in incentive salience and executive control among dependent smokers.


Description:

In a double-blind, randomized controlled trial, dependent smokers will be randomized to a 6-week very low nicotine content (VLNC) cigarette condition (N=50) or a 6-week normal nicotine content cigarette control condition (NNC; N=25). Participants will undergo functional magnetic resonance imaging (fMRI) scans at baseline and 6-weeks to investigate the nicotine-related modulation of brain circuitry involved in incentive salience valuation and executive control. Imaging tasks will engage the incentive salience of smoking cues and non-smoking rewards and executive control functions to identify changes in functional activity within, and effective connectivity between, known salience and executive control brain circuitry. A novel fMRI task using specialized odor presentation equipment and fMRI sequences will assess neural cue reactivity to smoke odors.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 39
Est. completion date January 2024
Est. primary completion date June 23, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 60 Years
Eligibility Inclusion Criteria: - 21-60 years old - Smoke >5 cigarettes per day - >1 year of daily smoking - No quit attempt in prior month and not planning to quit smoking within next 3 months - Able to understand and consent to study procedures - High school or lower educational attainment or annual household income < $50,000 - Plan to live in local area next 3 months - Women not pregnant or nursing and taking steps to avoid pregnancy - Able to read and write in English - Access to computer with internet service that allows for Zoom Exclusion Criteria: - Use of non-cigarette tobacco products in the past 7 days - Use of illicit substances more than once a week in the past 3 months (excluding marijuana) - Current alcohol abuse impairing participation - MRI safety contraindications (e.g., metal implants, claustrophobia) - Unstable or significant medical conditions (e.g., COPD, coronary heart disease) - Major neurological conditions or brain trauma - Major surgeries planned in next 3 months - Use of smoking cessation medication in prior month (e.g., varenicline, patch) - Uncontrolled serious mental illness, suicidality, or inpatient psychiatric hospitalization in the past 6 months - Unwillingness to provide urine samples - Unwilling to smoke study assigned cigarettes for the remainder of the trial - Plans to move or take extended travel out of the area in the next 3 months - Any other condition or situation that would, in the investigator's opinion, make it unlikely that the participant could comply with the study protocol - Self-reported color blindness - Left-handedness - Smell dysfunction as determined via standardized assessment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Very low nicotine content cigarettes
Very low nicotine content cigarettes
Normal nicotine content cigarettes
Normal nicotine content cigarettes

Locations

Country Name City State
United States Penn State Health Hershey Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Milton S. Hershey Medical Center National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in blood oxygen level dependent (BOLD) activity collected by fMRI Effect of nicotine content on changes in task-related functional brain activation over 6-weeks Changes in BOLD from baseline to the 6-week visit.
See also
  Status Clinical Trial Phase
Completed NCT01928719 - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status N/A
Completed NCT01995123 - Behavioral Activation for Smoking Cessation in PTSD N/A
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Recruiting NCT02564289 - Cardiovascular Effects of Chronic Snus Use N/A
Completed NCT01928758 - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Recruiting NCT00977249 - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users Phase 2/Phase 3
Active, not recruiting NCT00968513 - Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry Phase 3
Completed NCT01113424 - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum N/A
Completed NCT00747643 - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement N/A
Completed NCT00722124 - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Phase 2/Phase 3
Completed NCT01238627 - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg N/A
Completed NCT01228617 - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products N/A
Completed NCT00296647 - Smoking Cessation Intervention: Effectiveness in Primary Care Phase 4
Completed NCT00394420 - Emergency Department Telephone Quitline N/A
Recruiting NCT05487807 - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia Phase 1
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A